Live Oak Bank Names Susan Janson Chief Risk Officer

WILMINGTON, N.C., April 19, 2018 (GLOBE NEWSWIRE) -- Live Oak Bank announced today the appointment of Susan Janson as chief risk officer for the bank.  

Janson assumed the role effective April 16, and will oversee risk management, including regulatory relations and compliance. 

“Susan’s extensive experience and deep understanding of sound governance practices will play an integral role in Live Oak’s ability to scale our business model to better serve entrepreneurs and small business owners across the country,” said Live Oak Bank Chairman and CEO Chip Mahan.

Janson brings more than 30 years of financial and risk management experience to Live Oak. She previously served as senior capital markets and securities specialist for the Federal Deposit Insurance Corporation (FDIC) where she led regulatory risk assessments for financial institutions, including working with FDIC staff in Washington, DC, other federal and state agencies, and bankers to further understand and implement sound governance practices. Prior to that, she served as managing director at First National Capital Markets and Comerica Securities.

In addition to a career specializing in risk, capital markets, program leadership and team development, she received a BA in finance from Lawrence University in Southfield, MI. 

To learn more about Live Oak Bank, visit www.liveoakbank.com.

About Live Oak Bank
Live Oak Bank, a subsidiary of Live Oak Bancshares, Inc. (Nasdaq: LOB), is a digitally focused, FDIC-insured bank serving customers across the country. Live Oak brings efficiency and excellence to the banking process, without branches, by using a focused approach to technology and innovation. To learn more, visit www.liveoakbank.com.

Contact:
Micah Davis, Marketing Director
910.550.2255
[email protected]

Claire Parker, Senior Public Relations Manager
910.597.1592
[email protected]

You May Also Be Interested In

• Live Oak Bancshares names new principal accounting officer
• EnteroBiotix Announces First Patient Dosed in Phase 2b RISE Study of EBX-102-02 in Irritable Bowel Syndrome with Constipation
• iFAST Global Bank Expands Euro Payment Capabilities with SEPA Instant